Dopamine-synthesizing neurons: An overview of their development and application for cell therapy

Iranian Journal of Biotechnology

Volumn 8, Issue 4, 2010, Pages 219-228

  Gardaneh, Mossa ^a  

^a NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

Author keywords

Cell therapy; Dopamine; Dopaminergic; Parkinson disease

Indexed keywords

ALPHA SYNUCLEIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CYCLIC AMP; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 8; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE PEROXIDASE 1; LEVODOPA; NUCLEAR RECEPTOR RELATED FACTOR 1; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR MSX1; TRANSCRIPTION FACTOR PITX3; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; WNT1 PROTEIN; WNT5A PROTEIN; LIM PROTEIN; NEUROTRANSMITTER; PROTEIN LMX1B; UNCLASSIFIED DRUG;

BRAIN DEPTH STIMULATION; CELL SURVIVAL; CELL THERAPY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DYSKINESIA; EMBRYO DEVELOPMENT; GRAFT SURVIVAL; HUMAN; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; STEM CELL TRANSPLANTATION; STEREOTAXIC SURGERY; THERAPY EFFECT; CELL FUNCTION; CELL LINE; CELL TRANSPLANTATION; CENTRAL NERVOUS SYSTEM; CLINICAL EFFECTIVENESS; DEGENERATIVE DISEASE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL LESION;

MAMMALIA;

EID: 77957008082     PISSN: 17283043     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (164)

1. Ai Y, Markesbery W, Zhang Z, Grondin R, Elseberry D, Gerhardt GA, Gash DM (2003). Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol. 461: 250-261.
2. Akerud P, Canals JM, Snyder EY, Arenas E (2001). Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci. 21: 8108-8118.
3. Alavian KN, Scholz C, Simon HH (2008). Transcriptional regulation of mesencephalic dopaminergic neurons: the full circle of life and death. Mov Disord. 23: 19-28. Review.
4. Andersson E, Tryggvason U, Deng Q, Friling S, Alekseenko Z, Robert B, Perlmann T, Ericson J (2006). Identification of intrinsic determinants of midbrain dopamine neurons. Cell 124: 393-405.
5. Antoniades CA, Barker RA (2008). The search for biomarkers in Parkinson's disease: a critical review. Expert Rev Neurother. 8: 1841-52.
6. Apostolides C, Sanford E, Hong M, Mendez I (1998). Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells. Neuroscience 83: 363-372.
7. Aranguren XL, Luttun A, Clavel C, Moreno C, Abizanda G, Barajas MA, Pelacho B, Uriz M, Araña M, Echavarri A, Soriano M, Andreu EJ, Merino J, Garcia-Verdugo JM, Verfaillie CM, Prósper F (2007). In vitro and in vivo arterial differentiation of human multipotent adult progenitor cells. Blood 109: 2634-42.
8. Asbreuk CHJ, Vogelaar CF, Hellemons A, Smidt MP, Burbach JPH (2002). CNS expression pattern of Lmx1b and coexpression with Ptx genes suggest functional cooperativity in the development of forebrain motor control systems. Mol Cell Neurosci. 21: 410-420.
9. Bäckman C, Perlmann T, Wallén A, Hoffer BJ, Morales M (1999). A selective group of dopaminergic neurons express Nurr1 in the adult mouse brain. Brain Res. 851: 125-32.
10. Backman C, Zhang Y, Hoffer BJ, Tomac AC (2003). Short interfering RNAs (siRNAs) for reducing dopaminergic phenotypic markers. J Neurosci Methods. 131: 51-56.
11. Banday AA, Lokhandwala MF (2008). Dopamine receptors and hypertension. Curr Hypertens Rep. 10: 268-75. Review.
12. Bjorklund A, Dunnett SB (2007). Dopamine neuron systems in the brain: an update. Trends Neurosci. 30: 194-202.
13. Blaess S, Corrales JD, Joyner AL (2006). Sonic hedgehog regulates Gli activator and repressor functions with spatial and temporal precision in the mid/hindbrain region. Development 133: 1799-1809.
14. Blum M (1998). A null mutation in TGF-α leads to a reduction in midbrain dopaminergic neurons in substantia nigra. Nat Neurosci. 1: 374-77.
15. Boger HA, Middaugh LD, Huang P, Zaman V, Smith AC, Hoffer BJ, Tomac AC, Granholm AC (2006). A partial GDNF depletion leads to earlier age related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra Exp Neurol. 202: 336-347.
16. Brederlau A, Correia AS, Anisimov SV, Elmi M, Paul G, Roybon L, Morizane A, Bergquist F, Riebe I, Nannmark U, Carta M, Hanse E, Takahashi J, Sasai Y, Funa K, Brundin P, Eriksson PS, Li JY (2006). Transplantation of human embryonic stem cellderived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation, Stem Cells. 24: 1433-1440.
17. Briscoe J, Pierani A, Jessell TM, Ericson J (2000). Ahomeodomain protein code specifies progenitor cell identity and neuronal fate in the ventral neural tube. Cell 101: 435-445.
18. Buytaert-Hoefen KA, Alvarez E, Freed CR (2004). Generation of tyrosine hydroxylase positive neurons from human embryonic stem cells after coculture with cellular substrates and exposure to GDNF. Stem Cells 22: 669-674.
19. Cai J, Yang M, Poremsky E, Kidd S, Schneider JS, Iacovitti L (2009). Dopaminergic Neurons Derived from Human Induced Pluripotent Stem Cells Survive and Integrate into 6-OHDA Lesioned Rats. Stem Cells Dev. 2009 Oct 13 [Epub ahead of print]
20. Callier S, Snapyan M, Le Crom S, Prou D, Vincent JD, Vernier P (2003). Evolution and cell biology of dopamine receptors in vertebrates. Biol Cell. 95: 489-502. Review.
21. Carson CT, Aigner S, Gage FH (2006). Stem cells: the good, bad, and barely in control. Nat Med. 12: 1237-8.
22. Castelo-Branco G, Wagner J, Rodriguez FJ, Kele J, Sousa K, Rawal N, Pasolli HA, Fuchs E, Kitajewski J, Arenas E (2003). Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci USA. 100: 12747-12752.
23. Chinta SJ, Andersen JK (2005). Dopaminergic neurons. Int J Biochem Cell Biol. 37: 942-946. Review.
24. Cho MS, Lee YE, Kim JY, Chung S, Cho YH, Kim DS, Kang SM, Lee H, Kim MH, Kim JH, Leem JW, Oh SK, Choi YM, Hwang DY, Chang JW, Kim DW (2008). Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA. 105: 3392-3397.
25. Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH (2006). Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 494: 495-514.
26. Chung S, Sonntag KC, Andersson T, Bjorklund LM, Park JJ, Kim DW, Kang UJ, Isacson O, Kim KS (2002). Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. Eur J Neurosci. 16: 1829-1838.
27. Cooper O, Isacson O (2004). Intrastriatal transforming growth factor alpha delivery to a model of Parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons. J Neurosci. 24: 8924-8931.
28. Correia AS, Anisimov SV, Li JY, Brundin P (2008). Growth factors and feeder cells promote differentiation of human embryonic stem cells into dopaminergic neurons: a novel role for fibroblast growth factor-20. Front Neurosci. 2: 26-34.
29. Dahlstrom A, Fuxe K (1964). Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand. 62: 1-55.
30. Doudet DJ, Cornfeldt ML, Honey CR, Schweikert AW, Allen RC (2004). PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease, Exp Neurol. 189: 361-368.
31. Dunnett SB, Björklund A, Schmidt RH, Stenevi U, Iversen SD (1983). Intracerebral grafting of neuronal cell suspensions. IV. Behavioural recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites. Acta Physiol Scand Suppl. 522: 29-37.
32. Dunnett SB, Bentivoglio M, Bjurklund A, Hokfelt T (2005). Eds in "Handbook of Chemical Neuroanatomy" (A. Bjurklund, T. Hokfelt, eds), V.21: Dopamine, Chapters 5-8, Elsevier, Amsterdam.
33. Eller M, Williams DR (2009). Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol 5: 561-70.
34. Fahn S (2006). Levodopa in the treatment of Parkinson's disease. J Neural Transm Suppl. 71: 1-15. Review.
35. Falk T, Zhang S, Sherman SJ (2009). Pigment epithelium derived factor (PEDF) is neuroprotective in two in vitro models of Parkinson's disease. Neurosci Lett. 458: 49-52.
36. Fallon J, Reid S, Kinyamu R, Opole I, Opole R, Baratta J, Korc M, Endo TL, Duong A, Nguyen G, Karkehabadhi M, Twardzik D, Patel S, Loughlin S (2000). In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci USA. 97: 14686-14691.
37. Farkas LM, Dunker N, Roussa E, Unsicker K, Krieglstein K (2003). transforming growth factor-βs are essential for the development of midbrain dopaminergic neurons in vitro and in vivo. J Neurosci. 23: 5178-5186.
38. Freed CR, Greene PE, Breeze RE Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S (2001). Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 344: 710-9.
39. Frost EA, Osborn I (2009). Deep brain stimulation-surgery for movement disorders and Parkinson's disease. Int Anesthesiol Clin. 47: 57-68. Review.
40. Gardaneh M (2009). Cell-gene replacement therapy for Parkinson's disease. Proc Int Stem Cell Conf, September 21-22, University of Newcastle, Newcastle upon Tyne, UK
41. Gardaneh M, Gilbert J, Haber M, Norris MD, Cohn SL, Schmidt ML, Marshall GM (2000). Synergy between 5' and 3' flanking regions of the human tyrosine hydroxylase gene ensures specific, high-level expression in neuroblastoma cells. Neurosci Lett. 292: 147-150.
42. Gardaneh M, O'Malley KL (2004). Rat tyrosine hydroxylase promoter directs tetracycline-inducible foreign gene expression in dopaminergic cell types. Brain Res Mol Brain Res. 126: 173-180.
43. Gash, DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252-255.
44. Genzyme Press Release (2001). Porcine Xenografts http://www.genzyme.com/ corp/media/Genl%20PR%20-20041901.asp;http://www.genvec.com/go.cfm?do=Press.View&prid=141
45. German DC, Nelson EL, Liang CL, Speciale SG, Sinton CM, Sonsalla PK (1996). The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 5: 299-312.
46. German DC, Schlusselberg DS, Woodward DJ (1983). Threedimensional computer reconstruction of midbrain dopaminergic neuronal populations: from mouse to man. J Neural Transm. 57: 243-254.
47. German, DC, KF Manaye (1993). Midbrain dopaminergic neurons (nuclei A8, A9, and A10): Three-dimensional reconstruction in the rat. J Comp Neurol. 331: 297-309.
48. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P (2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 9: 589-95.
49. Glavaski-Joksimovic A, Virag T, Chang QA, West NC, Mangatu TA, McGrogan MP, Dugich-Djordjevic M, Bohn MC (2009). Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors. Cell Transplant Sep 28. [Epub ahead of print].
50. Grothe C, Timmer M, Scholz T, Winkler C, Nikkhah G, Claus P, Itoh N, Arenas E (2004). Fibroblast growth factor-20 promotes the differentiation of Nurr1-overexpressing neural stem cells into tyrosine hydroxylase-positive neurons. Neurobiol Dis. 17: 163-170.
51. Gurdon JB, Byrne JA (2003). The first half-century of nuclear transplantation. Proc Natl Acad Sci USA. 100: 8048-8052.
52. Hagell P, Brundin P (2001). Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol. 60: 741-752.
53. Hagell P, Piccini P, Björklund A, Brundin P, Rehncrona S, Widner H, Crabb L, Pavese N, Oertel WH, Quinn N, Brooks DJ, Lindvall O (2002). Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci. 5: 627-628.
54. Hara K, Matsukawa N, Yasuhara T, Xu L, Yu G, Maki M, Kawase T, Hess DC, Kim SU, Borlongan CV (2007). Transplantation of post-mitotic human neuroteratocarcinoma-overexpressing Nurr1 cells provides therapeutic benefits in experimental stroke: in vitro evidence of expedited neuronal differentiation and GDNF secretion. J Neurosci Res. 85: 1240-1251
55. Hedlund E, Pruszak J, Ferree A, Viñuela A, Hong S, Isacson O, Kim KS (2007). Selection of embryonic stem cell-derived enhanced green fluorescent protein-positive dopamine neurons using the tyrosine hydroxylase promoter is confounded by reporter gene expression in immature cell populations. Stem Cells 25: 1126-1135.
56. Hedlund E, Pruszak J, Lardaro T, Ludwig W, Viñuela A, Kim KS, Isacson O (2008). Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease. Stem Cells 26: 1526-1536.
57. Heijtz RD, Kolb B, Forssberg H (2007). Motor inhibitory role of dopamine D1 receptors: implications for ADHD. Physiol Behav. 92: 155-160.
58. Hellmich HL, Kos L, Cho ES, Mahon KA, Zimmer A (1996). Embryonic expression of glial cell-line derived neurotrophic factor (GDNF) suggests multiple developmental roles in neural differentiation and epithelial-mesenchymal interactions. Mech Dev. 54: 95-105.
59. Hermanson E, Joseph B, Castro D, Lindqvist E, Aarnisalo P, Wallén A, Benoit G, Hengerer B, Olson L, Perlmann T (2003). Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. Exp Cell Res. 288: 324-334.
60. Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, Agid Y (1997). Neuronal vulnerability in Parkinson's disease. J Neural Transm Suppl. 50: 79-88. Review.
61. Ho KS, Scott MP (2002). Sonic hedgehog in the nervous system/functions, modifications and mechanisms. Curr Opin Neurobiol. 12: 57-63.
62. Hwang DY, Ardayfio P, Kang UJ, Semina EV, Kim KS (2003). Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res. 114: 123-31.
63. Hwang DY, Hong S, Jeong JW, Choi S, Kim H, Kim J, Kim KS (2009). VMAT2 and DAT are molecular targets of Pitx3 in the ventral midbrain dopamine neurons. J Neurochem Sep 24. [Epub ahead of print].
64. Hynes M, Stone DM, Dowd M, Pitts-Meek S, Goddard A, Gurney A, Rosenthal A (1997). Control of cell pattern in the neural tube by the zinc finger transcription factor and oncogene Gli-1. Neuron 19: 15-26.
65. Ito R, Asami S, Kagawa S, Motohashi S, Shichino H, Chin M, Yoshida Y, Nemoto N, Mugishima H, Suzuki T (2004). Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma. Biol Pharm Bull. 27: 315-318.
66. Iwawaki T, Kohno K, Kobayashi K (2000). Identification of a potential Nurr1 response element that activates the tyrosine hydroxylase gene promoter in cultured cells. Biochem Biophys Res Commun. 274: 590-595.
67. Joksimovic M, Yun BA, Kittappa R Anderegg AM, Chang WW, Taketo MM, McKay RD, Awatramani RB (2009). Wnt antagonism of Shh facilitates midbrain floor plate neurogenesis. Nat Neurosci. 12: 125-131.
68. Kawasaki H, Mizuseki K, Nishikawa S, Kaneko S, Kuwana Y, Nakanishi S, Nishikawa SI, Sasai Y (2000). Induction of midbrain dopaminergic neurons from ES cells by stromal cellderived inducing activity. Neuron 28: 31-40.
69. Kim DW, Chung S, Hwang M, Ferree A, Tsai HC, Park JJ, Chung S, Nam TS, Kang UJ, Isacson O, Kim KS (2006). Stromal cell-derived inducing activity, Nurr1, and signaling molecules synergistically induce dopaminergic neurons from mouse embryonic stem cells. Stem Cells 24: 557-567.
70. Kim JH, Auerbach JM, Rodríguez-Gómez JA, Velasco I, Gavin D, Lumelsky N, Lee SH, Nguyen J, Sánchez-Pernaute R, Bankiewicz K, McKay R (2002). Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418: 50-56.
71. Kim KS, Kim CH, Hwang DY, Seo H, Chung S, Hong SJ, Lim JK, Anderson T, Isacson O (2003). Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner. J Neurochem. 85: 622-634.
72. Kim TE, Lee HS, Lee YB, Hong SH, Lee YS, Ichinose H, Kim SU, Lee MA (2003). Sonic hedgehog and FGF8 collaborate to induce dopaminergic phenotypes in the Nurr1-overexpressing neural stem cell. Biochem Biophys Res Commun. 305: 1040-1048.
73. Kondo T (2002). Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. J Neurol. 249: 25-29. Review.
74. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW (2008). Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 14: 504-506.
75. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290: 767-773.
76. Korecka JA, Verhaagen J, Hol EM (2008). Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease. Regen Med. 2: 425-46. Review.
77. Korotkova TM, Ponomarenko AA, Haas HL, Sergeeva OA (2005). Differential expression of the homeobox gene Pitx3 midbrain in dopaminergic neurons. Eur J Neurosci. 22: 1287-1293.
78. Le WD, Conneely OM, Zou L, He Y, Saucedo-Cardenas O, Jankovic J, Mosier DR, Appel SH (1999). Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol. 159: 451-458.
79. Lee SH, Lumelsky N, Studer L, Auerbach JM, McKay RD (2000). Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol. 18: 675-679.
80. Levy YS, Bahat-Stroomza M, Barzilay R, Burshtein A, Bulvik S, Barhum Y, Panet H, Melamed E, Offen D (2008). Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy. 10: 340-352.
81. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P (2008). Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med. 14: 501-503.
82. Li L, Su Y, Zhao C, Xu Q (2009). Role of Nurr1 and Ret in inducing rat embryonic neural precursors to dopaminergic neurons. Neurol Res. 31: 534-540.
83. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993). GDNF: a glial cell-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
84. Lui KO, Waldmann H, Fairchild PJ (2009). Embryonic stem cells overcoming the immunological barriers to cell replacement therapy. Curr Stem Cell Res Ther. 4: 70-80.
85. Luo Y, Henricksen LA, Giuliano RE, Prifti L, Callahan LM, Federoff HJ (2007). VIP is a transcriptional target of Nurr1 in dopaminergic cells. Exp Neurol. 203: 221-232.
86. Madhavan L, Daley BF, Paumier KL, Collier TJ (2009). Transplantation of subventricular zone neural precursors induces an endogenous precursor cell response in a rat model of Parkinson's disease. J Comp Neurol. 515: 102-115.
87. Mandel RJ, Brundin P, Bjorklund A (1990). The importance of graft placement and task complexity for transplant-induced recovery of simple and complex sensorimotor deficits in dopamine denervated rats. Eur J Neurosci. 2: 888-894.
88. McLaughlin D, Tsirimonaki E, Vallianatos G, Sakellaridis N, Chatzistamatiou T, Stavropoulos-Gioka C, Tsezou A, Messinis I, Mangoura D (2006). Stable expression of a neuronal dopaminergic progenitor phenotype in cell lines derived from human amniotic fluid cells. J Neurosci Res. 83: 1190-1200.
89. Mendez I, Hong M, Smith S, Dagher A, Desrosiers J (2000). Neural transplantation cannula and microinjector system: experimental and clinical experience. Technical note. JNeurosurg. 92: 493-499.
90. Miller GW, Gainetdinov RR, Levey AI, Caron MG (1999). Dopamine transporters and neuronal injury. Trends Pharmacol Sci. 20: 424-429.
91. Missale C, Nash SR, Robinson SW, Mohamed J, Caron MG (1998). Dopamine Receptors: From Structure to Function. Physiol Rev. 7: 189-225.
92. Mohapel P, Frielingsdorf H, Haggblad J, Zachrisson O, Brundin P (2005). Platelet-derived growth factor (PDGF-BB) and brainderived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions. Neuroscience 132: 767-776.
93. Montgomery EB (1999). Deep brain stimulation reduces symptoms of Parkinson disease. Cleve Clin J Med. 66: 9-11.
94. Morizane A, Takahashi J, Shinoyama M, Ideguchi M, Takagi Y, Fukuda H, Koyanagi M, Sasai Y, Hashimoto N (2006). Generation of graftable dopaminergic neuron progenitors from mouse ES cells by a combination of coculture and neurosphere methods. J Neurosci Res. 83: 1015-1027.
95. Nagatsu T (1991) Genes for human catecholamine-synthesizing enzymes. Neurosci Res. 12: 315-345.
96. Nagatsu T, Ichinose H (1999). Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin. Mol Neurobiol. 19: 79-96. Review.
97. Nagatsu T, Levit M, Udenfriend S (1964). Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J. Biol. Chem. 239: 2910-2917.
98. Nelson EL, Liang CL, Sinton CM, German DC (1996). Midbrain dopaminergic neurons in the mouse/computer-assisted mapping. J Comp Neurol. 369: 361-371.
99. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP (2003). A doubleblind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 54: 403-414.
100. Ootsuka S, Asami S, Sasaki T, Yoshida Y, Nemoto N, Shichino H, Chin M, Mugishima H, Suzuki T (2008). Useful markers for detecting minimal residual disease in cases of neuroblastoma. Biol Pharm Bull. 31: 1071-1074.
101. Pakkenberg B, Moller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H (1991). The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry. 54: 30-33.
102. Panhuysen M, Vogt Weisenhorn DM, Blanquet V, Brodski C, Heinzmann U, Beisker W, Wurst W (2004). Effects of Wnt1 signaling on proliferation in the developing mid-/hindbrain region. Mol Cell Neurosci. 26: 101-11.
103. Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gómez-Díaz R, López-Barneo J (2008). Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci. 11: 755-761.
104. Perlmann T, Wallén-Mackenzie A(2004). Nurr1, an orphan nuclear receptor with essential functions in developing dopamine cells. Cell Tissue Res. 318: 45-52.
105. Perrier AL, Tabar V, Barberi T, Rubio ME, Bruses J, Topf N, Harrison NL, Studer L (2004). Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA. 34: 12543-8.
106. Phillips AG, Vacca G, Ahn S (2008). A top-down perspective on dopamine, motivation and memory. Pharmacol Biochem Behav. 90: 236-249.
107. Placzek M, Briscoe J (2005). The floor plate: multiple cells, multiple signals. Nat Rev Neurosci. 6: 230-240.
108. Prakash N, Brodski C, Naserke T, Puelles E, Gogoi R, Hall A, Panhuysen M, Echevarria D, Sussel L,Weisenhorn DMV, Martinez S, Arenas E, Simeone A, Wurst W(2006a). AWnt1-regulated genetic network controls the identity and fate of midbrain-dopaminergic progenitors in vivo. Development 133: 89-98.
109. Prakash N, Wurst W (2006b). Development of dopaminergic neurons in the mammalian brain. Cell Mol Life Sci 63:187-206.
110. Pruszak J, Sonntag KC, Aung MH, Sanchez-Pernaute R, Isacson O (2007). Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. Stem Cells 25: 2257-2268.
111. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C (2002). Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 359: 1589-1598.
112. Revazova ES, Turovets NA, Kochetkova OD, Agapova LS, Sebastian JL, Pryzhkova MV, Smolnikova VI, Kuzmichev LN, Janus JD (2008). HLA homozygous stem cell lines derived from human parthenogenetic blastocysts. Cloning Stem Cells. 10: 11-24.
113. Revazova ES, Turovets NA, Kochetkova OD, Kindarova LB, Kuzmichev LN, Janus JD, Pryzhkova MV (2007). Patientspecificstem cell lines derived from human parthenogenetic blastocysts. Cloning Stem Cells. 9: 432-449.
114. Reynolds GP (1996). Dopamine receptors and schizophrenia. Biochem Soc Trans. 24: 202-205. Review.
115. Rhinn M, Brand M (2001). The midbrain- hindbrain boundary organizer. Curr Opin Neurobiol. 11: 34-42.
116. Robertson NJ, Brook FA, Gardner RL, Cobbold SP, Waldmann H, Fairchild PJ (2007). Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc Natl Acad Sci USA. 104: 20920-20925.
117. Rosenblad C, Martinez-Serrano A, Bjorklund A (1998). Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 82: 129-137.
118. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA (2006). Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomeraseimmortalized midbrain astrocytes. Nat Med. 12: 1259-1268.
119. Sacchetti P, Brownschidle LA, Granneman JG, Bannon MJ (1999). Characterization of the 5'-flanking region of the human dopamine transporter gene. Brain Res Mol Brain Res. 74: 167-174.
120. Sakurada K, Ohshima-Sakurada M, Palmer TD, Gage FH (1999). Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 126: 4017-4026.
121. Sandhu JK, Gardaneh M, Iwasiow R, Lanthier P, Gangaraju S, Ribecco-Lutkiewicz M, Tremblay R, Kiuchi K, Sikorska M (2009). Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity. Neurobiol Dis. 33: 405-414.
122. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, Smidt MP, Cox JJ, De Mayo F, Burbach JP, Conneely OM (1998). Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci USA. 95: 4013-4018.
123. Sayles M, Jain M, Barker RA (2004). The cellular repair of the brain in Parkinson's disease-past, present and future. Transpl Immunol. 12: 321-342.
124. Schulz TC, Noggle SA, Palmarini GM, Weiler DA, Lyons IG, Pensa KA, Meedeniya AC, Davidson BP, Lambert NA, Condie BG (2004). Differentiation of human embryonic stem cells to dopaminergic neurons in serum-free suspension culture. Stem Cells. 22: 1218-1238.
125. Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, Fischman AJ, Thomas C, Feldman RG, Kassissieh S, Raineri R, Manhart C, Penney D, Fink JS, Isacson O (2000). Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 54: 1042-1050.
126. Shamekh R, Saporta S, Cameron DF, Willing AE, Sanberg CD, Johe K, Sanberg PR (2008). Effects of Sertoli cell-conditioned medium on ventral midbrain neural stem cells: a preliminary report. Neurotox Res. 13: 241-246.
127. Shim JW, Park CH, Bae YC, Bae JY, Chung S, Chang MY, Koh HC, Lee HS, Hwang SJ, Lee KH, Lee YS, Choi CY, Lee SH (2007). Generation of functional dopamine neurons from neural precursor cells isolated from the subventricular zone and white matter of the adult rat brain using Nurr1 overexpression. Stem Cells 25: 1252-1262.
128. Shimada H, Yoshimura N, Tsuji A, Kunisada T (2009). Differentiation of dopaminergic neurons from human embryonic stem cells: modulation of differentiation by FGF-20. J Biosci Bioeng. 107: 447-254.
129. Shintani A, Nakao N, Kakishita K, Itakura T. (2008) Generation of dopamine neurons from embryonic stem cells in the presence of the neuralizing activity of bone marrow stromal cells derived from adult mice. J Neurosci Res. 86: 2829-38.
130. Simon HH, Saueressig H, Wurst W, Goulding MD, O'Leary DD (2001). Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J Neurosci. 21: 3126-3134.
131. Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, Walton A, Wagner R, Young AB (2006). Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. Neurosurg Focus. 20: E1.
132. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B (2005). Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg. 102: 216-222.
133. Smidt MP, Asbreuk CH, Cox JJ, Chen H, Johnson RL & Burbach JP (2000). A second independent pathway for development of mesencephalic dopaminergic neurons requires Lmx1b. Nat Neurosci. 3: 337-341.
134. Smidt MP, Smits SM, Bouwmeester H, Hamers FP, Linden AJ vander, Hellemons AJ, Graw J, Burbach JP (2004a). Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3. Development 131: 1145-1155.
135. Smidt MP, Smits SM, Burbach JP (2004b). Homeobox gene Pitx3 and its role in the development of dopamine neurons of the substantia nigra. Cell Tissue Res. 318: 35-43.
136. Smith Y, Kieval JZ (2000). Anatomy of the dopamine system in the basal ganglia. Trends Neurosci 23 (Suppl): S28-S33
137. Smits SM, Ponnio T, Conneely OM, Burbach JP, Smidt MP (2003). Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons. Eur J Neurosci. 18: 1731-1738.
138. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R (2009). Parkinson's disease patient derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136: 964-977.
139. Sonntag KC, Pruszak J, Yoshizaki T, van Arensbergen J, Sanchez-Pernaute R, Isacson O (2007). Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. Stem Cells 25: 411-418.
140. Sonntag KC, Simantov R, Kim KS, Isacson O (2004). Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation. Eur J Neurosci. 19: 1141-1152.
141. Storch A, Sabolek M, Milosevic J, Schwarz SC, Schwarz J (2004). Midbrain-derived neural stem cells: from basic science to therapeutic approaches. Cell Tissue Res. 318: 15-22.
142. Subramanian T, Marchionini D, Potter EM, Cornfeldt ML (2002). Striatal xenotransplantation of human retinal pigment epithelial cells attached to microcarriers in hemiparkinsonian rats ameliorates behavioral deficits without provoking a host immune response. Cell Transplant. 11: 207-214.
143. Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y, Fukuda H, Okamoto Y, Koyanagi M, Ideguchi M, Hayashi H, Imazato T, Kawasaki H, Suemori H, Omachi S, Iida H, Itoh N, Nakatsuji N, Sasai Y, Hashimoto N (2005). Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest. 115: 102-109.
144. Takahashi H, Higuchi M, Suhara T (2006). The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol Psychiatry. 59: 919-928. Review.
145. Takahashi K, Yamanaka S (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
146. Tomac, A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L (1995). Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373: 335-339.
147. Träger C, Vernby A, Kullman A, Ora I, Kogner P, Kågedal B (2008). mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with highrisk disease when measured at diagnosis. Int J Cancer. 123: 2849-55.
148. Tseng KY, Roubert C, Do L, Rubinstein M, Kelly MA, Grandy DK, Low MJ, Gershanik OS, Murer MG, Giros B, Raisman-Vozari R (2000). Selective increase of Nurr1 mRNA expression in mesencephalic dopaminergic neurons of D2 dopamine receptor-deficient mice. Brain Res Mol Brain Res. 80: 1-6.
149. Vallone D, Picetti R, Borrelli E. (2000) Structure and function of dopamine receptors. Neurosci Biobehav Rev. 24: 125-132. Review.
150. Van den Munckhof P, Luk KC, Ste-Marie L, Montgomery J, Blanchet PJ, Sadikot AF, Drouin J (2003). Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development 130: 2535-2542.
151. Vazin T, Becker KG, Chen J, Spivak CE, Lupica CR, Zhang Y, Worden L, Freed WJ (2009). A novel combination of factors, termed SPIE, which promotes dopaminergic neuron differentiation from human embryonic stem cells. PLoS One. 4: e6606.
152. Vazin T, Chen J, Lee CT, Amable R, Freed WJ (2008). Assessment of stromal-derived inducing activity in the generation of dopaminergic neurons from human embryonic stem cells. Stem Cells 26: 1517-25.
153. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F (2007). Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol. 64: 1575-1579. Review.
154. Wallen AA, Castro DS, Zetterstrom RH, Karlen M, Olson L, Ericson J, Perlmann T (2001). Orphan nuclear receptor Nurr1 is essential for Ret expression in midbrain dopamine neurons and in the brain stem. Mol Cell Neurosci. 18: 649-663.
155. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R (2008). Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA. 105: 5856-5861.
156. Wijeyekoon R, Barker RA (2009). Cell replacement therapy for Parkinson's disease. Biochim Biophys Acta 1792: 688-702.
157. Wise RA (2004). Dopamine, learning and motivation. Nat Rev Neurosci. 5: 483-494.
158. Wood TK, McDermott KW, Sullivan AM (2005). Differential effects of growth/ differentiation factor 5 and glial cell linederived neurotrophic factor on dopaminergic neurons and astroglia in cultures of embryonic rat midbrain. J Neurosci Res. 80: 759-66.
159. Yan Y, Yang D, Zarnowska ED, Du Z, Werbel B, Valliere C, Pearce RA, Thomson JA, Zhang SC (2005). Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells. Stem Cells 23: 781-790.
160. Yang D, Zhang ZJ, Oldenburg M, Ayala M, Zhang SC (2008). Human embryonic stem cell derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells. 26: 55-63.
161. Ye W, Shimamura K, Rubenstein JL, Hynes MA, Rosenthal A (1998). FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. Cell 93: 755-766.
162. Yue F, Cui L, Johkura K, Ogiwara N, Sasaki K (2006). Induction of midbrain dopaminergic neurons from primate embryonic stem cells by coculture with sertoli cells. Stem Cells 24: 1695-1706.
163. Zafeiriou DI, Willemsen MA, Verbeek MM, Vargiami E, Ververi A, Wevers R (2009). Tyrosine hydroxylase deficiency with severe clinical course. Mol Genet Metab. 97: 18-20.
164. Zeng X, Cai J, Chen J, Luo Y, You ZB, Fotter E, Wang Y, Harvey B, Miura T, Backman C, Chen GJ, Rao MS, Freed WJ (2004). Dopaminergic differentiation of human embryonic stem cells. Stem Cells 22: 925-940